Inhibitor

(redirected from matrix metalloproteinase inhibitor)
Also found in: Dictionary, Thesaurus, Medical, Legal.

inhibitor

[in′hib·əd·ər]
(aerospace engineering)
A substance bonded, taped, or dip-dried onto a solid propellant to restrict the burning surface and to give direction to the burning process.
(chemistry)
A substance which is capable of stopping or retarding a chemical reaction; to be technically useful, it must be effective in low concentration.

Inhibitor

 

a circuit having m + n inputs and a single output, at which a signal can appear only when there are no signals on the m inputs (inhibiting). The other n inputs (principal) form one of the two logic connections, “AND” or “OR.” Inhibitors are used extensively in computers. They are very often understood to be a circuit having a single principal input and a single inhibiting input. A signal appears at the output of such a circuit when a signal is present on the principal input but there is none on the inhibiting input. Such an inhibitor is called an anticoincidence gate; its conventional representation is given in Figure 1.

Figure 1. Block diagram of an anticoincidence gate (inhibitor) with m — 1 and n 1:(A) principal input, (Q) inhibiting input, (Ga) anticoincidence gate

inhibitor

A substance added to paint to retard drying, skinning, mildew growth, etc. Also see corrosion inhibitor, inhibiting pigment, drying inhibitor.
References in periodicals archive ?
Marimastat is a matrix metalloproteinase inhibitor and a potential anti-cancer treatment that has been licensed to Schering-Plough Corporation.
7 /PRNewswire/ -- Schering-Plough Corporation (NYSE: SGP) and British Biotech plc today announced a licensing agreement to develop and commercialize British Biotech's matrix metalloproteinase inhibitors (MMPIs), including marimastat and BB-3644, for the treatment of cancer.
Study 140, a clinical trial of the oral matrix metalloproteinase inhibitor, marimastat, in patients with small cell lung cancer, has been completed and the data have been collected.
Matrix Metalloproteinase Inhibitor Prevents Acute Lung Injury After Cardiopulmonary Bypass, Circulation, 1999;100:400-406.
British Biotech (NASDAQ:BBIOY) announces the results of Study 186, a clinical trial of the oral matrix metalloproteinase inhibitor, marimastat.
British Biotech announces the results of Study 131, a Phase III clinical trial of the oral matrix metalloproteinase inhibitor, marimastat.
BB-2827 is a collagenase-selective matrix metalloproteinase inhibitor.
Matrix metalloproteinase inhibitors in rheumatic diseases.
Overall, Linder recommended using a formula that contains broad-spectrum UV protection, matrix metalloproteinase inhibitors (MMPi), antioxidants, retinoids, ascorbic acid and peptides to improve collagen and matrix protection and production.

Full browser ?